Night shift work and chronic lymphocytic leukemia in the MCC-spain case-control study

Abstract

Chronic lymphocytic leukaemia (CLL) has few known modifiable risk factors.

Recently, circadian disruption has been proposed as a potential contributor to lymphoid neoplasms' etiology.

Serum melatonin levels have been found to be significantly lower in CLL subjects compared with healthy controls, and also, CLL prognosis has been related to alterations in the circadian molecular signaling.

We performed the first investigation of an association between night shift work and CLL in 321 incident CLL cases and 1728 population-based controls in five areas of Spain. Participants were interviewed face-to-face by trained interviewers to collect information on socio-demographic factors, familial, medical and occupational history, including work shifts, and other lifestyle factors.

We used logistic regression models adjusted for potential confounders to estimate odds ratios (OR) and 95% confidence intervals (CI).

Seventy-nine cases (25%) and 339 controls (20%) had performed night work. Overall, working in night shifts was not associated with CLL (OR=1.06; 95%CI=0.78-1.45, compared with day work). However, long-term night shift (>20 years) was positively associated with CLL (OR(tertile 3 vs. day-work) = 1.77; 95%=1.14-2.74), although no linear trend was observed (P-trend =0.18).

This association was observed among those with rotating (OR(tertile 3 vs. day-work) = 2.29; 95%CI=1.33-3.92; P-trend = 0.07), but not permanent night shifts (OR(tertile 3 vs. day-work) = 1.16; 95%CI=0.60-2.25; P-trend = 0.86).

The association between CLL and long-term rotating night shift warrants further investigation.

About this publication.

See also:

- About Melatonin;

- Chronic Lymphocytic Leukemia: Long-Lasting Remission with Combination of Cyclophosphamide, Somatostatin, Bromocriptine, Retinoids, Melatonin, and ACTH;

- The Di Bella Method (DBM) in the treatment of prostate cancer: a preliminary retrospective study of 16 patients and a review of the literature;

- Evaluation of the safety and efficacy of the first-line treatment with somatostatin combined with melatonin, retinoids, vitamin D3, and low doses of cyclophosphamide in 20 cases of breast cancer: a preliminary report;

- The Di Bella Method (DBM) improved survival, objective response and performance status in a retrospective observational clinical study on 122 cases of breast cancer;

- Complete objective response to biological therapy of plurifocal breast carcinoma;

- Cyclophosphamide plus Somatostatin, Bromocriptin, Retinoids, Melatonin and ACTH in the Treatment of Low-grade Non-Hodgkin’s Lymphomas at Advanced Stage: Results of a Phase II Trial;

- Relapse of High-Grade Non-Hodgkin’s Lymphoma After Autologous Stem Cell Transplantation: A Case Successfully Treated With Cyclophosphamide Plus Somatostatin, Bromocriptine, Melatonin, Retinoids, and ACTH;

- Low-grade Non-Hodgkin Lymphoma at Advanced Stage: A Case Successfully Treated With Cyclophosphamide Plus Somatostatin, Bromocriptine, Retinoids, and Melatonin;

- The Di Bella Method (DBM) improved survival, objective response and performance status in a retrospective observational clinical study on 55 cases of Lymphomas.